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Vorinostat, a histone deacetylase (HDAC) inhibitor, has
shown evidence of single-agent activity in glioblastoma
(GBM), and in preclinical studies, we have demonstrated
significant synergistic cytotoxicity between HDAC inhi-
bitors and proteasome inhibitors in GBM cell lines. We
therefore conducted a phase II trial to evaluate the effi-
cacy of vorinostat in combination with the proteasome
inhibitor bortezomib in patients with recurrent GBM.
Vorinostat was administered at a dose of 400 mg daily
for 14 days of a 21-day cycle, and bortezomib was admi-
nistered at a dose of 1.3 mg/m2 intravenously on days 1,
4, 8, and 11 of the cycle. A total of 37 patients were
treated, and treatment was well tolerated: grade 3, 4
nonhematologic toxicity occurred in 30% of patients
and consisted mainly of fatigue (14%) and neuropathy
(5%); grade 3, 4 hematologic toxicity occurred in 37%
of patients and consisted of thrombocytopenia (30%),
lymphopenia (4%), and neutropenia (4%). The trial
was closed at the predetermined interim analysis, with
0 of 34 patients being progression-free at 6 months.
One patient achieved a partial response according to
the Macdonald criteria. The median time to progression
for all patients was 1.5 months (range, 0.5–5.6 months),
and median overall survival (OS) was 3.2 months.
Patients who had received prior bevacizumab therapy
had a shorter time to progression and OS, compared
with those who had not. On the basis of the results of
this phase II study, further evaluation of the vorino-
stat-bortezomib combination in GBM patients in this
dose and schedule is not recommended.
Keywords: bortezomib, phase II trial, recurrent
glioblastoma, vorinostat.
G
lioblastoma (GBM) is a refractory malignancy.
Despite surgical resection, external beam radi-
ation therapy, and chemotherapy, median sur-
vival is only 15–18 months.1,2 There is an urgent need
to develop novel therapeutic strategies for this disease.
Vorinostat (suberoylanilide hydroxamic acic;
MW ¼ 264) is a linear hydroxamic acid that inhibits
class I and class II histone deacetylases (HDACs),3,4
causing hyperacetylation of core histone proteins H2A,
H2B, H3, and H4.5 Hyperacetylation of nuclear his-
tones causes changes in chromatin structure that ultim-
ately result in changes in gene expression. In addition,
the acetylation state of several other proteins, including
a-tubulin and hsp90, increases after treatment with vor-
inostat.6 The biological effects of HDAC inhibition by
vorinostat are widespread. Indeed, treatment with
HDAC inhibitors results in changes in 2%–10% of all
expressed genes.7,8 Vorinostat and other HDAC inhibi-
tors have demonstrated preclinical activity in a broad
range of solid tumor and hematological malignancies,
both in in vitro and animal models.6
Several HDAC inhibitors, including vorinostat, have
demonstrated preclinical activity against GBM cell
lines and glioma models.9–11 On the basis of this
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strong preclinical rationale, North Central Cancer
Treatment Group (NCCTG) completed a phase II trial
of vorinostat in patients with recurrent GBM.12
Vorinostat was well tolerated in this patient population
and met its primary end point, with 9 of the first 52
patients being progression-free at 6 months (15%
progression-free at 6 months [PFS6], compared with a
,10% PFS6 of historic controls). Paired baseline and
post–vorinostat treatment tumor samples demonstrated
increased histone acetylation consistent with the
expected target effect. Vorinostat-based combination
regimens therefore represent a rational next step to
build on the modest single agent activity, while capital-
izing on the favorable toxicity profile.
Bortezomib (N-pyrazinecarbonyl-L-phenylalanine-L-
leucine boronic acid) is a small, cell-permeable molecule,
entering via passive diffusion, that specifically and
selectively inhibits the proteasome by binding in a re-
versible manner. It is a modified dipeptidyl boronic
acid derived from leucine and phenylalanine that inhibits
the 20S proteasome with a Ki of 0.6 nM. The ordered,
temporal degradation of numerous key short-lived regu-
latory proteins by the proteasome (such as p53, p21,
p27, cyclins, cyclin-dependent kinase inhibitors, and
tumor suppressors) is required for cell-cycle progression,
cell survival, and metastasis.13 The major biological
effects of bortezomib include inhibition of NF-kB,
CDK activity, angiogenesis, and cellular adhesion and
induction of PTEN, p53, p21, p27, ROS, and
apoptosis.14,15
There is preclinical evidence that bortezomib has
antitumor activity against malignant glioma cell lines.
Bortezomib induces growth arrest and apoptosis in
established human GBM cell lines.16 The observed
growth inhibition is attributable to a G2/M phase cell-
cycle arrest and is associated with increased expression
of the cell-cycle inhibitors p21WAF1 and p27KIP1 and
decreased expression of cyclin dependant kinases.
Bortezomib also activated apoptosis in 35%–40% of
GBM lines, in part through stimulation of the
pro-apoptotic kinase JNK and down regulation of the
prosurvival proteins Bcl-2 and Bcl-xl. With use of 2 dif-
ferent human GBM cell lines, bortezomib demonstrated
higher cytotoxicity, compared with a panel of anti
cancer agents, including temozolamide and carbopla-
tin.17 Early evidence of clinical activity has been demon-
strated in a phase I trial in patients with recurrent
GBM.18 Although the primary end point of the trial
was to determine the maximum tolerated dose of borte-
zomib, 2/66 patients experienced a partial response. Of
importance, proteasome activity was inhibited by 79%
in whole blood at bortezomib doses below the
maximum tolerated dose.
We have demonstrated that the combination of
HDAC and proteasome inhibitors has in vitro synergistic
cytotoxicity in GBM cell lines and short-term cultures of
patient-derived tumor samples maintained as mouse
xenografts.19 Cytoxicity was assessed using multiple
assays for cell proliferation and viability, including
MTS assays, annexin V/propidium iodide staining
with flow cytometry, and morphological analysis of
apoptotic cells using DAPI staining. Synergisitic interac-
tions were confirmed using the median effect method of
Chou and Talalay,20 which was partially mediated by
stimulation of Bax conformational changes and subse-
quent mitochondrial translocation that initiated the
apoptotic cascade. In preparation for this trial, we con-
ducted preclinical in vitro experiments testing the
vorinostat-bortezomib combination in short-term cul-
tures derived from tumor samples from patients with
GBM and maintained as mouse xenografts. Synergistic
in vitro cytotoxicity between vorinostat and bortezomib
was also demonstrated (B. Friday and C. Yu, unpub-
lished data). Thus, the synergism between HDAC and
proteasome inhibitors against glioma cell lines appears
to represent a class effect.
The combination of vorinostat and bortezomib has
been tested in 2 phase I trials.21,22 The doses determined
to be the MTD in both studies were similar (vorinostat at
400 mg and bortezomib at 1.3 mg/m2). The combin-
ation has a reasonable toxicity profile, with thrombo-
cytopenia being the most common toxicity seen in
both studies, and demonstrated encouraging phase I ac-
tivity in heavily pretreated patients with multiple
myeloma and sarcoma.
On the basis of the rationale described above, this
study was designed to assess the clinical efficacy of vor-
inostat in combination with bortezomib in patients with
recurrent GBM.
Patients and Methods
Patient Eligibility Criteria
Eligible patients were 18 years of age or older and had a
histologic confirmation of GBM or gliosarcoma at
primary diagnosis or recurrence. Patients were required
to be receiving a stable dose of corticosteroids or no cor-
ticosteroids for 1 week or more before their baseline
imaging. A minimum of 8 weeks from completion of ra-
diation therapy was required for study entry. Patients
could have received no more than one prior chemother-
apy regimen for progressive or recurrent disease and had
to have their last chemotherapy treatment at least 4
weeks or more prior to study entry (≥6 weeks if nitro-
sourea was administered). They were also required to
have an Eastern Cooperative Oncology Group perform-
ance score of 0–2; acceptable hematologic function,
defined as absolute neutrophil count ≥ 1500 neutro-
phils/mL, platelet count ≥100 000 platelets/mL, and
hemoglobin level ≥8 g/dL; adequate hepatic and renal
function, defined as total bilirubin level less than or
equal to the upper limit of normal (ULN), aspartate ami-
notransferase level ≤ 3 × ULN, and creatinine level
≤1.5 × ULN. Patients who were receiving valproic
acid (or other HDAC inhibitors) or enzyme-inducing
anti-epileptic drugs should have had these discontinued
for at least 2 weeks prior to study entry to become eli-
gible. Patients receiving enzyme-inducting anti-epileptic
drugs, including carbamazepine, phenytoin, fospheny-
toin, phenobarbital, and primidone, were excluded.
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Patients with grade 2 or greater neuropathy at baseline
were excluded from the study. Patients were required
to sign an Institutional Review Board–approved
consent form prior to study entry.
Treatment Administration
Vorinostat was administered at a dose of 400 mg orally
once daily on days 1–14 of a 21-day cycle. Bortezomib
was administered at a dose of 1.3 mg/m2 on days 1, 4,
8, and 11 of a 21-day cycle. Toxicity was graded accord-
ing to the Common Terminology Criteria, version 3.0.
Patients with grade 2 or less toxicity continued treatment
at the starting dose until progressive disease. For the first
occurrence of grade 3 hematological and nonhematolo-
gical toxicity, vorinostat and bortezomib were reduced
by 25% in subsequent cycles, but the toxicity had to
improve to less than or equal to grade 1 prior to resum-
ing therapy. For recurrent grade 3 or grade 4 toxicity
after initial dose reduction, doses of both medications
were reduced by an additional 33% (vorinostat) and
25% (bortezomib). With further grade 3 or greater tox-
icity after the second dose reduction, patients were with-
drawn from study treatment. If the first occurrence of
significant toxicity was grade 4, doses were initially
reduced by 50% (vorinostat) and 40% (bortezomib).
With recurrent grade 3 or higher toxicity, patients were
withdrawn from study treatment. For grade 3 or greater
neuropathy, only the bortezomib was dose reduced.
Definition of Response
Neuroimaging with MRI was performed at baseline,
before the third treatment cycle, and every second
cycle thereafter. For patients with measurable disease,
a modification of the Macdonald criteria were used for
response assessment.23
For patients with evaluable but not measurable
disease, regression was defined as unequivocal reduction
in size of contrast enhancement or decrease in mass
effect as determined by primary physician and quality
control physicians and no new lesion, with the patient
receiving stable or decreased corticosteroid dose. A com-
plete response was defined as the total disappearance of
all tumor with patient off corticosteroids or only receiv-
ing adrenal replacement maintenance. Progression was
defined as unequivocal increase in size of contrast en-
hancement or increase in mass effect as assessed by
primary physician and quality control physicians or ap-
pearance of new lesions. Patients with imaging findings
not meeting criteria for complete response, regression,
or progression were determined to have stable disease.
Statistical Considerations and Methodology
A 1-stage phase II design with interim analysis based on
Simon’s MinMax design was used.24 The primary end
point of the trial was the percentage of patients alive
and PFS6. Secondary end points included confirmed
tumor response, overall survival, and time to
progression. The study was designed to test the hypoth-
esis that addition of bortezomib to vorinostat would in-
crease the PFS6 rate from 15%, which is the PFS6 rate
observed in the NCCTG single agent vorinostat trial,12
to more than 30%. The trial had 91% power, with an
a error of 0.10 to declare the regimen active, if the
true PFS6 rate met or exceeded 30%. The study design
required a total of 53 patients. An interim analysis was
planned after the first 34 evaluable patients had been fol-
lowed up for at least 6 months; the study would continue
if more than 5 successes were observed in these 34
patients.
Time to progression was defined as time from study
entry to disease progression; patients who died were con-
sidered to have disease progression at time of death
unless there was documented evidence that no progres-
sion occurred before death. Overall survival was
defined as time from study entry to death from any
cause. Patients who have not died or experienced
disease progression were censored at last known follow-
up. Associations of categorical baseline outcome and
translational data were tested using x2 and Fisher’s
exact tests. Comparisons of continuous baseline,
outcome, and translational data were tested using
Wilcoxon rank-sum test. Survival and time to progression
curves were compared using the log-rank test; Cox pro-
portional hazards models were used to assess the relation-
ship between time-to-event end points and outcome.
Results
Patient Characteristics
Thirty-eight patients were enrolled in the study between
from August 29, 2008 through February 15, 2010; one
patient was excluded from subsequent analysis because
of cancellation prior to treatment initiation. Table 1
lists the characteristics of the 37 patients participating
in the trial. Most of the patients (59%) had received
prior therapy for recurrent disease. Prior therapies for
glioblastoma, both as initial therapy and for recurrent
disease, included temozolamide (100%), bevacizumab
(43%), and nitrosoureas (8%). A significant number of
patients were receiving corticosteroids at the time of
study enrollment (59%).
Response and Outcome Assessment
The trial failed to meet the interim analysis threshold for
continuation. None of the first 34 patients were progres-
sion free at 6 months. All 37 patients completed treat-
ment, with the median number of treatment cycles
being 2 (range, 1–8 cycles). Reasons for study with-
drawal included disease progression (32 of 37), patient
refusal (3 of 27), and adverse events (2 of 37). The
median time to progression was 1.5 months (range,
0.5–5.6 months). The median overall survival from
study entry was 3.2 months (range, 0.7–24.8 months),
with one patient still alive. Patients who had received
prior bevacizumab therapy (n ¼ 16) had a shorter
Friday et al.: Phase II trial of vorinostat with bortezomib in recurrent GBM
NEURO-ONCOLOGY † F E B R U A R Y 2 0 1 2 217
median time to progression (1.3 months), compared
with those who had no prior bevacizumab therapy (1.7
months; P ¼ .0627). Similarly, median OS was shorter
in the group who received prior bevacizumab, as
compared with those who did not (2.7 vs 5.6 months;
P ¼ .0017). Kaplan-Meier plots demonstrating time to
progression and OS relative to prior bevacizumab
therapy are presented in Fig. 1. Patient characteristics
were analyzed for differences between the bevacizumab-
naive and bevacizumab-refractory groups, including
sex, age, prior therapies, and corticosteroid use.
Only the number of prior chemotherapy regimens
was statistically different between these 2 groups, with
bevacizumab-pretreated patients having received a
significantly higher number of prior chemotherapy regi-
mens (P ¼ .0024). Despite the poor prognosis following
progression during bevacizumab therapy and study pto-
tocol, the patients who had received prior bevacizumab
therapy had a longer median overall survival, as
measured from initial GBM diagnosis (16.7 vs 13.9
months). Objective responses were infrequent. Only
one patient achieved a partial objective response.
Toxicity
Figure 2 summarizes treatment-related toxicity observed
in the trial. Grade 3–4 hematologic toxicity was
observed in 37% of the patients, with the most
common toxicities being thrombocytopenia (2% grade
3, 28% grade 4), neutropenia (2% grade 3, 2% grade
4), and lymphopenia (4% grade 3). The overall inci-
dence of grade 3–4 nonhematologic toxicity was 30%,
with the most common toxicity being fatigue (14%
grade 3). Overall, 14 (56%) of the 25 patients who
received multiple treatment cycles required dose reduc-
tion as a result of toxicity. Adverse events were the
reason for study withdrawal for 2 (5%) of the 37
patients treated in the study.
Discussion
Combining HDAC inhibition with vorinostat and prote-
asome inhibition with bortezomib represents a rational
therapeutic combination in GBM treatment. A prior
single-agent study using vorinostat in recurrent GBM
demonstrated modest single-agent activity, with a 15%
PFS6 rate, compared with the less than 10% PFS6 rate
of historical controls.12 Clinical activity has also been
described for the proteasome inhibitor bortezomib in
malignant glioma, with 2 patients achieving a partial
response in a phase I trial.18 Preclinical synergistic
cytoxicity between HDAC inhibitors and proteasome
inhibitors has been demonstrated in glioma cell lines,19
Fig. 1. Kaplan–Meier plots stratified by prior bevacizumab use
relative to time to progression (TTP); (A) and overall survival
(OS); (B). Prior bevacizumab treatment is associated with a
reduced TTP, but the difference was not statistically significant
(P ¼ .0627). Prior bevacizumab is associated with a significantly
reduced OS (P ¼ .0017).
Table 1. Patient Baseline Characteristics (n ¼ 37)
Characteristic No. %
Sex
Female 10 27
Male 27 73
Age, years
Median 51.5
Range 33–80
Performance Score
0 8 22
1 19 51
2 10 27
No. of prior chemotherapy
regimens for recurrent disease
0 15 41
1 22 59
Prior temozolomide
Adjuvant 37 100
Recurrent 7 19
Prior bevacizumab
Yes 16 43
No 21 57
Prior nitrosourea
Yes 3 8
No 34 92
Corticosteroid therapy at enrollment
Yes 22 59
No 15 41
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which were confirmed in this report using vorinostat and
bortezomib. The combination exerts a synergistic
cytoxic effect in glioma cell lines that is mediated, in
part, through stimulation of Bax translocation to the
mitochondria and subsequent apoptotic cell death.19
Preclinical data also support synergisitic cytotoxicity
between HDAC and proteasome inhibitors in a variety
of other cancer types, including squamous cell head
and neck,25 cutaneous T-cell lymphoma,26 hepatoma,27
and multiple myeloma.28 This NCCTG study was
undertaken to evaluate the efficacy of vorinostat in com-
bination with bortezomib in patients with recurrent
GBM.
Despite a strong scientific rationale supporting the ef-
ficacy of the combination, the trial was closed at the first
interim efficacy analysis, because none of the first 34
patients were progression free at 6 months. The
median overall survival of the 37 patients who received
treatment was only 3.2 months. These data compare un-
favorably with the single-agent vorinostat study, in
which the PFS6 rate was 15% and the median overall
survival was 5.7 months.12 Although these differences
may just reflect statistical variation because of the rela-
tively small patient numbers, they also may suggest
that there is an antagonistic interaction between borte-
zomib and vorinostat in vivo, despite the in vitro
synergy.19 Although this study did not include pharma-
cokinetic analyses, a phase I study of vorinostat and bor-
tezomib in patient with multiple myeloma using a
similar dosing schedule did not find a significant differ-
ence between vorinostat pharmacokinetics as a single
agent, compared with the combination,21 when vorino-
stat was administered once daily, as in this trial.
Vorinostat was administered in a twice daily schedule
in the prior single-agent study in patients with GBM.
Because of the half-life of the agent, 2 h for vorinostat,
the administration schedule in the 2 trials has likely
resulted in different peak and trough vorinostat expo-
sures, which could also have impacted on clinical
efficacy.
Compared with other anatomical cancer sites, the
brain provides unique therapeutic challenges. Access of
drugs through the blood-brain barrier is of particular
concern. There is convincing evidence that vorinostat
can access the central nervous system (CNS). First, vor-
inostat was shown to cross the blood-brain Barrier in a
mouse model of Huntington’s disease.29 Second, vorino-
stat inhibited the growth of GL26 GBM cells implanted
into the brains of mice.11 Finally, vorinostat treatment
induced accumulation of acetylated histones H2B, H3,
and H4 in patients with recurrent GBM.12 Unlike vori-
nostat, there is no clear evidence that bortezomib can
cross an intact blood-brain barrier or penetrate into
CNS tumors. In rats treated with bortezomib using a
multidose regimen similar to this trial, bortezomib was
found at very low concentrations in the CNS.30
Similarly, bortezomib only reaches low concentrations
in the CNS of nonhuman primates.31 These observations
are corroborated by clinical experience. In one report, a
patient with progressive multiple myeloma was treated
with bortezomib and had a good hematological re-
sponse.32 Unfortunately, the patient developed progres-
sive CNS myeloma despite the ongoing systemic
hematological response. The lack of efficacy observed
in this trial may therefore also reflect the inability of bor-
tezomib to access the CNS at concentrations needed to
Fig. 2. Most frequently observed treatment-related toxicities for patients with glioblastoma (GBM) receiving vorinostat and bortezomib.
Most toxicities were grade 1 and 2. The most frequent hematologic grade 3 and 4 toxicity was thrombocytopenia, and the most
frequent nonhematologic toxicity was fatigue.
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exert synergistic cytotoxicity in combination with
vorinostat.
The statistical design for this study was based on the
results of N047B, a phase II NCCTG trial of vorinostat
in recurrent GBM.12 Since completion of N047B, the
therapeutic landscape for patients with recurrent GBM
has changed substantially with the Food and Drug
Administration–accelerated approval of the anti-VEGF
antibody bevacizumab. After study entry, bevacizumab
pretreatment was associated with significantly shorter
PFS and OS. This is unlikely to represent a negative
effect of the regimen, because accumulating data
suggest that progression after bevacizumab therapy is
associated with poor prognosis and rapid clinical
decline.33–36 In addition to prior bevacizumab expos-
ure, however, other negative prognostic factors might
have contributed to the worse outcome in these patients.
For example, bevacizumab-refractory patients had also
received a significantly higher number of prior chemo-
therapy regimens (P ¼ .0024). Although the possible
impact of prior bevacizumab therapy may have negative-
ly affected our results, even among the 21 patients
treated without prior bevacizumab exposure, none
were progression free at 6 months. Nevertheless, these
data, in conjunction with data derived from other
groups,34–36 support that trials in patients with recur-
rent GBM should be separately powered depending on
prior bevacizumab therapy.
In summary, despite a strong scientific and clinical ra-
tionale for combining vorinostat and bortezomib in
patients with recurrent GBM, this combination is clinic-
ally ineffective, and further development of this combin-
ation in treatment of recurrent GBM is not warranted.
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